

CONTENTS

| | |
|--|----------|
| PREFACE | xv |
| ACKNOWLEDGMENTS | xxxi |
| ABBREVIATIONS | xxxiii |
| SECTION 1 NORMAL FUNCTIONAL HIGH-DENSITY LIPOPROTEIN | 1 |
| 1 COMPOSITION | 3 |
| 1.1 Proteome / 9 | |
| Apolipoproteins / 9 | |
| <i>Apolipoprotein A-I</i> / 9 | |
| <i>ApoA-II</i> / 9 | |
| <i>ApoA-IV</i> / 9 | |
| <i>ApoA-V</i> / 10 | |
| <i>ApoC-I, ApoC-II, ApoC-III, ApoC-IV</i> / 12 | |
| <i>ApoD</i> / 12 | |
| <i>ApoE</i> / 13 | |
| <i>ApoF</i> / 14 | |
| <i>ApoH</i> / 14 | |
| <i>ApoJ</i> / 14 | |
| <i>ApoL-I</i> / 15 | |

viii CONTENTS

| | |
|---|-----------|
| <i>ApoM</i> / 15 | |
| <i>Other Apolipoproteins</i> / 15 | |
| Enzymes / 16 | |
| <i>LCAT</i> / 16 | |
| <i>PON1 and PON3</i> / 16 | |
| <i>PAF-AH (LpPLA2)</i> / 17 | |
| <i>GSPx-3</i> / 18 | |
| Lipid Transfer Proteins / 18 | |
| <i>PLTP</i> / 18 | |
| <i>CETP</i> / 19 | |
| Acute-Phase Response Proteins / 19 | |
| <i>Serum Amyloid A</i> / 19 | |
| <i>Other Proteins</i> / 20 | |
| Complement Components / 21 | |
| Proteinase Inhibitors and Related Proteins / 23 | |
| Other Protein Components / 25 | |
| 1.2 Lipidome / 27 | |
| Phospholipids / 27 | |
| Steroids / 28 | |
| Cholesteryl Esters / 28 | |
| Triglycerides / 28 | |
| Minor Lipids / 28 | |
| 2 HETEROGENEITY | 39 |
| 2.1 Heterogeneity in Physicochemical Properties / 42 | |
| Heterogeneity in Density / 42 | |
| Heterogeneity in Electrophoretic Mobility / 43 | |
| Heterogeneity in Size / 45 | |
| 2.2 Heterogeneity in Chemical Composition / 47 | |
| Heterogeneity in Proteins / 47 | |
| Heterogeneity in Lipids / 49 | |
| 2.3 Relationships Between HDL Subfractions Separated by Different Methods / 50 | |
| 3 STRUCTURE | 59 |
| 3.1 Lipid-Free ApoA-I / 59 | |
| 3.2 Discoid HDL / 62 | |
| 3.3 Spherical HDL / 66 | |

| | |
|--|------------|
| 4 METABOLISM | 74 |
| 4.1 Formation and Intravascular Remodeling / 74 | |
| ABC Transporters / 77 | |
| <i>ABCA1</i> / 77 | |
| <i>ABCG1</i> / 85 | |
| Enzymes / 86 | |
| <i>LCAT</i> / 86 | |
| <i>Lipases</i> / 88 | |
| Lipid Transfer Proteins / 90 | |
| <i>CETP</i> / 90 | |
| <i>PLTP</i> / 92 | |
| Receptors / 93 | |
| <i>SR-BI</i> / 93 | |
| 4.2 Catabolism / 96 | |
| 5 EPIDEMIOLOGY | 113 |
| 5.1 Epidemiology of HDL-C / 113 | |
| HDL-C and Cardiovascular Risk / 113 | |
| <i>Relevance Across Multiple Populations and Disease States</i> / 116 | |
| <i>HDL-C and Other Cardiovascular Risk Factors</i> / 120 | |
| <i>Prevalence of Low HDL-C</i> / 122 | |
| <i>HDL-C and Cardiovascular Risk in Patients Receiving Statins</i> / 123 | |
| HDL-C and Other Major Diseases / 125 | |
| 5.2 Epidemiology of HDL-Associated Proteins and Enzymes / 126 | |
| ApoA-I / 126 | |
| Other Apolipoproteins / 129 | |
| SAA / 130 | |
| PON1 / 130 | |
| PAF-AH / 131 | |
| Other Enzymes / 133 | |
| Lipid Transfer Proteins / 133 | |
| 5.3 Epidemiology of HDL Particle Subpopulations / 134 | |
| Separated by Density / 134 | |
| Separated by Electrophoretic Mobility / 135 | |
| Separated by Composition / 135 | |
| Separated by Size / 135 | |

6 GENETICS 161

- 6.1 ABC Transporters and Other Receptors / 165
 - ABCA1 / 165
 - SR-BI / 167
 - LDL Receptor / 167
- 6.2 Apolipoproteins / 167
 - ApoA-I / 167
 - ApoA-V / 168
 - ApoC-III / 168
 - ApoE / 168
- 6.3 Enzymes / 169
 - LCAT / 169
 - PON1 / 169
 - LPL / 170
 - Hepatic Lipase / 171
 - Endothelial Lipase / 171
- 6.4 Lipid Transfer Proteins / 172
 - CETP / 172
- 6.5 Other Genes / 174
- 6.6 Gene Interactions / 176

7 BIOLOGIC ACTIVITIES 192

- 7.1 Cholesterol Efflux Capacity / 197
 - Mechanisms of Cellular Cholesterol Efflux / 199
 - ABCA1-Mediated Efflux / 199*
 - ABCG1-Mediated Efflux / 203*
 - SR-BI-Mediated Efflux / 204*
 - Other Pathways / 205*
 - Role of HDL Components / 206
 - Proteins / 206*
 - Lipids / 208*
 - Functional Heterogeneity of HDL / 210
- 7.2 Antioxidative Activity / 213
 - Mechanisms of Protection Against Oxidative Stress / 216
 - Role of HDL Components / 219
 - Apolipoproteins / 219*
 - Enzymes / 220*
 - Lipids / 223*

| | | |
|-----|--|--|
| | Functional Heterogeneity of HDL / 224 | |
| 7.3 | Anti-Inflammatory Activity / 226 | |
| | Mechanisms of Anti-Inflammatory Protection / 231 | |
| | Role of HDL Components / 234 | |
| | <i>Proteome</i> / 234 | |
| | <i>Lipidome</i> / 235 | |
| | Functional Heterogeneity of HDL / 236 | |
| 7.4 | Cytoprotective Activity / 236 | |
| | Mechanisms of Cytoprotection / 238 | |
| | Role of HDL Components / 241 | |
| | <i>Proteome</i> / 241 | |
| | <i>Lipidome</i> / 241 | |
| | Functional Heterogeneity of HDL / 242 | |
| 7.5 | Anti-Infectious Activity / 243 | |
| | Mechanisms of Protection from Infection / 245 | |
| | Role of HDL Components / 246 | |
| | <i>Proteome</i> / 246 | |
| | <i>Lipids</i> / 248 | |
| | Functional Heterogeneity of HDL / 248 | |
| 7.6 | Vasodilatory Activity / 249 | |
| | Mechanisms of Vasodilatory Activity / 250 | |
| | Role of HDL Components / 252 | |
| | <i>Proteins</i> / 252 | |
| | <i>Lipids</i> / 252 | |
| | Functional Heterogeneity of HDL / 253 | |
| 7.7 | Antithrombotic Activity / 253 | |
| | Mechanisms of Antithrombotic Effects / 256 | |
| | Role of HDL Components / 257 | |
| | Functional Heterogeneity of HDL / 258 | |
| 7.8 | Antidiabetic Activity / 259 | |

SECTION 2 FUNCTIONALLY DEFECTIVE HDL 305

8 ALTERED COMPOSITION 307

| | |
|-----|----------------------------|
| 8.1 | <i>Proteome</i> / 307 |
| 8.2 | <i>Lipidome</i> / 311 |
| 8.3 | Enzymatic Activities / 313 |

9 ABNORMAL METABOLISM 329

- 9.1 Dyslipidemias / 329
- 9.2 Insulin-Resistant States / 337
- 9.3 Inflammatory States / 339
- 9.4 Infectious Diseases / 341
- 9.5 Cardiovascular Disease / 342
- 9.6 Post-Prandial State / 343
- 9.7 Smoking / 344

10 IMPAIRED BIOLOGIC ACTIVITIES 360

- 10.1 Cholesterol Efflux Capacity / 361
 - Dyslipidemia / 361
 - Role of HDL Components / 364*
 - Insulin Resistance / 365
 - Role of HDL Components / 367*
 - Inflammation / 369
 - Cardiovascular Disease / 372
 - Pathophysiologic Relevance / 373
- 10.2 Antioxidative Activity / 373
 - Dyslipidemia / 373
 - Role of HDL Components / 374*
 - Insulin Resistance / 376
 - Role of HDL Components / 376*
 - Inflammation / 379
 - Infection / 380
 - Cardiovascular Disease / 380
 - Pathophysiologic Relevance / 381
- 10.3 Anti-Inflammatory Activity / 382
 - Dyslipidemia / 382
 - Insulin Resistance / 385
 - Inflammation / 386
 - Cardiovascular Disease / 388
 - Pathophysiologic Relevance / 389
- 10.4 Cytoprotective Activity / 391
- 10.5 Vasodilatory Activity / 392
- 10.6 Anti-Infectious Activity / 394
- 10.7 Antithrombotic Activity / 395

| | |
|--|------------|
| SECTION 3 THERAPEUTIC NORMALIZATION OF SUBNORMAL LEVELS AND DEFECTIVE BIOLOGIC ACTIVITIES OF HDL | 417 |
| 11 ENHANCEMENT OF HDL FORMATION AND NORMALIZATION OF INTRAVASCULAR HDL REMODELING | 423 |
| 11.1 Apolipoproteins / 423 | |
| 11.2 Reconstituted HDL / 428 | |
| Effects on HDL Levels and Metabolism / 428 | |
| Effects on HDL Functionality / 430 | |
| Role of HDL Components / 432 | |
| 11.3 Apolipoprotein-Mimetic Peptides / 434 | |
| Effects on HDL Levels and Metabolism / 434 | |
| Effects on HDL Functionality / 434 | |
| 11.4 Statins / 440 | |
| Effects on HDL Levels and Metabolism / 440 | |
| Effects on HDL Functionality / 444 | |
| Clinical Trials / 446 | |
| 11.5 PPAR Alpha Agonists / 447 | |
| Effects on HDL Levels / 447 | |
| Mechanisms of Action / 448 | |
| Effects on HDL Functionality / 451 | |
| Clinical Trials / 452 | |
| 11.6 Nicotinic Acid / 454 | |
| Mechanisms of Action / 455 | |
| Clinical Trials / 458 | |
| Effects on HDL Functionality / 460 | |
| Adverse Effects / 461 | |
| 11.7 CETP Inhibitors / 463 | |
| Torcetrapib / 464 | |
| Dalcetrapib / 467 | |
| Anacetrapib / 467 | |
| Effects on RCT / 469 | |
| Clinical Trials / 471 | |
| Effects on HDL Functionality / 474 | |
| 11.8 Other Agents / 477 | |
| LXR Agonists / 477 | |
| PPAR Gamma Agonists / 478 | |

| | |
|--|------------|
| Lipase Inhibitors / 479 | |
| <i>sPLA₂ Inhibitors / 480</i> | |
| <i>Endothelial Lipase Inhibitors / 481</i> | |
| <i>LpPLA₂ Inhibitors / 481</i> | |
| SR-BI Inhibitors / 482 | |
| Others / 483 | |
| 12 COMBINATION THERAPIES | 524 |
| 12.1 Niacin and Statins / 524 | |
| 12.2 Fibrates and Statins / 527 | |
| 12.3 Other Combinations / 528 | |
| 13 OTHER PHARMACOLOGIC APPROACHES | 533 |
| 13.1 Cannabinoid Type 1 Receptor Antagonists / 533 | |
| 13.2 Estrogens / 536 | |
| 13.3 Others / 538 | |
| 14 LIFESTYLE MODIFICATIONS | 542 |
| 14.1 Exercise / 542 | |
| 14.2 Alcohol / 546 | |
| 14.3 Nutritional Factors / 548 | |
| Dietary Fats / 548 | |
| <i>Cholesterol / 548</i> | |
| <i>Phospholipids / 549</i> | |
| <i>Saturated Fatty Acids / 549</i> | |
| <i>Monounsaturated Fatty Acids / 550</i> | |
| <i>PUFAs / 550</i> | |
| Carbohydrates / 552 | |
| Proteins / 553 | |
| Minor Dietary Components / 554 | |
| <i>Polyphenols / 554</i> | |
| <i>Vitamins / 556</i> | |
| <i>Other Minor Components / 556</i> | |
| CONCLUSIONS AND PERSPECTIVES | 572 |
| INDEX | 577 |